Hope Care, a Portuguese digital health company specialising in regulated remote patient monitoring technology, has closed a €6 million Series A funding round.
The round was led by Iberis Capital, with participation from Vieira de Matos – VDM Capital, S.A. and existing shareholder Buenavista Equity Partners.
José Paulo Carvalho, founder and CEO of Hope Care, said, “This Series A marks a new stage for Hope Care. After more than a decade working with healthcare institutions, we have built a regulated platform that delivers measurable outcomes for patients, healthcare professionals and healthcare systems. With the support of our investors, we are now well positioned to accelerate our European expansion and bring this model of care to more healthcare organisations.”
Founded in 2012, Hope Care develops OpMA, a regulated platform that powers centralised remote care and telehealth centres. The company states that it brings together medical device data, patient-reported outcomes, and clinical workflows in a single environment. The platform enables healthcare organisations to design, deploy and scale digital care programmes across multiple chronic conditions, supporting proactive intervention and more efficient care delivery.
The company currently delivers remote patient monitoring programmes in Portugal and France, including within GHT Saône-et-Loire Bresse Morvan, and has a project underway in Switzerland.
In Germany, it has recently established Hope Care GmbH, headquartered at Medical Valley in Erlangen. The company’s first German deployment is scheduled to launch in October 2026. In Romania, the digital health startup is advancing a new project and establishing a local presence, with setup activities scheduled to begin by the end of September 2026.
The company also reported that in Portugal, its technology is used by 15 Local Health Units covering approximately 45% of all registered SNS users, as well as the Regional Health Services of Madeira and the Azores. Beyond the public health system, the platform is also deployed across private healthcare providers, social care organisations and municipalities.
Hope Care also claims that its programmes have demonstrated measurable clinical and economic impact. In a 12-month analysis of 43 people living with chronic obstructive pulmonary disease, one programme was associated with a 76% reduction in hospital days and a 74% reduction in emergency department visits, resulting in estimated annual savings of €4,811 per patient.
“Across Europe, health systems are straining under the weight of chronic disease, still responding to crises rather than preventing them. Hope Care is one of the few companies that pairs proven clinical evidence with the regulatory maturity to operate inside public health systems at scale. This is a model we are proud to help scale across Europe, since it helps clinicians improve outcomes for patients and ultimately the sustainability of care,” said João Henriques, Partner at Iberis Capital.
The company plans to use this capital to support Hope Care’s continued expansion across Europe, strengthen its commercial and operational capabilities, and accelerate the deployment of remote patient monitoring programmes in key healthcare markets.
Hope Care continued to grow in 2026, with first-half sales reaching 2.5 times the first-half level of 2025.
